[Federal Register Volume 84, Number 191 (Wednesday, October 2, 2019)]
[Notices]
[Pages 52519-52520]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21459]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploring Epigenomic or Non-Coding RNA Regulation in 
the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 
Clinical Trial Optional).
    Date: October 4, 2019.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4228, MSC 95509529, 301-827-4471, 
Bethesda, MD 20892, [email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Device-Based Treatments for Substance Use Disorders 
(UG3/UH3) (Clinical Trial Optional).
    Date: October 8, 2019.
    Time: 10:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 
301-827-5833, [email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; National Drug Early Warning System Coordinating 
Center (U01 Clinical Trial Optional).
    Date: October 21, 2019.
    Time: 12:00 p.m. to 2:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 
4238, MSC 9550, Bethesda, MD 20892, 301-402-6020, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Rapid Assessment of Drug Abuse: Smart City Tools.
    Date: October 24, 2019.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug, Abuse National Institutes of Health, DHHS, 6001 Executive 
Blvd. Room 4235 MSC 9550, Bethesda, MD 20892-9550, 301-827-5819, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Providing Research Education Experiences to Enhance 
Diversity in the Next Generation of Substance Abuse and Addiction 
Scientists (R25--Clinical Trials Not Allowed).
    Date: October 28, 2019.
    Time: 8:30 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 
4238, MSC 9550, Bethesda, MD 20892, 301-402-6020, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Alcohol

[[Page 52520]]

and Other Substance Use Research Education Programs for Health 
Professionals and NIDA Research Education Program for Clinical 
Researchers and Clinicians.
    Date: October 28, 2019.
    Time: 12:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 
4238, MSC 9550 Bethesda, MD 20892, 301-402-6020, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploiting Omics Assays to Investigate Molecular 
Regulation of Persistent HIV in Individuals with Substance Use 
Disorder (R61/R33 Clinical Trial Optional).
    Date: October 31, 2019.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4228, MSC 95509529, 301-827-4471, 
Bethesda, MD 20892, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Digital Health Technologies to Address the Social 
Determinants of Health in context of Substance Use Disorders (SUD).
    Date: November 1, 2019.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive 
Blvd. Room 4235 MSC 9550, Bethesda, MD 20892-9550, 301-827-5819, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; R13 Conference Grant Review.
    Date: December 9-10, 2019.
    Time: 8:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Virtual Meeting).
    Contact Person: Yvonne Owens Ferguson, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH/DHHS, 
6001 Executive Blvd., Rm. 4234, Bethesda, MD 20892, 301-402-7371, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: September 27, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-21459 Filed 10-1-19; 8:45 am]
 BILLING CODE 4140-01-P